Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

GenSpera adds trial site to G-202 phase I clinical program

Dec. 3, 2010

Chugai Pharma presents in vivo data on new potential cancer therapeutics

Dec. 3, 2010

Agennix discloses interim data from first-in-human trial of RGB-286638 in hematologic tumors

Dec. 3, 2010

Oncolytics Biotech begins enrollment in phase II Reolysin study in ovarian cancer

Dec. 2, 2010

FDA to request further information for Cavatak IND for phase II melanoma trial

Dec. 2, 2010

Medivation and Astellas complete enrollment in phase III MDV-3100 trial

Dec. 2, 2010

Phase I trial of INK-128 initiated in multiple myeloma

Dec. 2, 2010

Elara Pharma's new antitumor agent EL-102 inhibits HIF-1-alpha and cellular proliferation

Dec. 2, 2010

PI3K-delta inhibitor XL-499 shows promising preclinical activity

Dec. 2, 2010

Pfizer's phase III axitinib trial in renal cell carcinoma meets primary endpoint

Dec. 1, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...